Table 3. Treatment with LM in combination with carboplatin/etoposide is superior to chemotherapy alone against subcutaneous NCI-H526 SCLC xenografts.
| Treatment | LM dose (mg/kg) | T/C (%) | CR | Tumor-free (day 111) | Response |
|---|---|---|---|---|---|
| LM single agent | 8.5 | 5 | 3 of 6 | 3 of 6 | highly active |
| 5.7 | 50 | 0 of 6 | 0 of 6 | inactive | |
| 2.8 | 103 | 0 of 6 | 0 of 6 | inactive | |
| 1.4 | 82 | 0 of 6 | 0 of 6 | inactive | |
| Carboplatin/etoposide | - | 16 | 0 of 6 | 0 of 6 | active |
| LM/carboplatin/etoposide combination | 8.5 | 0 | 5 of 6 | 5 of 6 | highly active |
| 5.7 | 0 | 5 of 6 | 4 of 6 | highly active | |
| 2.8 | 0 | 5 of 6 | 3 of 6 | highly active | |
| 1.4 | 5 | 1 of 6 | 1 of 6 | highly active |
SCID mice bearing established NCI-H526 xenografts were treated with: LM (qw × 2) at doses of 8.5 mg/kg (MED) and at reduced doses of 5.7, 2.8 and 1.4 mg/kg; carboplatin (100 mg/kg qd × 1)/ etoposide (3 mg/kg qd × 5), and combinations of LM and carboplatin/etoposide. T/C = median tumor volumes of treated (T)/control (C) animals when control tumors reached an average volume of 1000 mm3 (day 15); study ended on day 111.